profit from every $100 of sales.
$0$100
SI-BONE
$23.44-2.90% today
+35.8% in 1 year
1-year low $11.611-year high $25.60
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What SI-BONE sold, what it kept, and what it did with the cash.
Sales went from $106 million in 2022 to $201 million in 2025, with -$18.9 million of profit last year.
SalesProfit
SI-BONE vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| SI-BONE | No profit yet | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Steris | 32.8× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price |
AI analysis
An AI analyst reads SI-BONE's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 106 | 139 | 167 | 201 | |
| 91 | 109 | 132 | 160 | |
| -60 | -47 | -35 | -22 | |
| -55 | -34 | -23 | -11 | |
| -61 | -43 | -31 | -19 | |
| -1.79 | -1.13 | -0.75 | -0.44 | |
| 85.2% | 78.8% | 79.0% | 79.6% | |
| -56.0% | -33.8% | -21.1% | -11.1% | |
| -57.6% | -31.2% | -18.5% | -9.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 158 | 230 | 230 | 239 |
| Cash | 21 | 33 | 35 | 42 |
| Total debt | 39 | 39 | 37 | 37 |
| Total liabilities | 59 | 61 | 63 | 61 |
| 98 | 169 | 167 | 178 | |
| 34 | 38 | 41 | 43 | |
| -33.5% | -15.1% | -10.6% | -6.0% | |
| -62.3% | -25.6% | -18.5% | -10.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -42 | -19 | -12 | -1 | |
| 10 | 8 | 10 | 8 | |
| -51 | -27 | -23 | -9 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 23 | 24 | 26 | 26 |
Valuation
- –
- –
- –
- 3.5×
- 5.3×
- –
- –
- -0.9%
- -1.8%
- 0.0%
Profitability
- 79.6%
- -11.1%
- -9.4%
- -3.6%
- -9.0%
- -24.7%
- -9.6%
- -6.9%
- -9.0%
- 8.3%
Growth
- +23.6%
- –
- +60.3%
- –
- +7.0%
Financial health
- -0.5×
- 0.04
- 3.0%
- -7.8×
- 9.99
- 8.34
- 0.85
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 22%of 963
Bottom 14%of 894
Top 23%of 908
Bottom 31%of 991
What analysts expect
- Average price target
- $25.25
- Range
- $23.00 – $27.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.10 | -0.17 | +41.2% |
| Feb 23, 2026 | -0.04 | -0.13 | +69.2% |
| Nov 10, 2025 | -0.11 | -0.16 | +31.3% |
| Aug 4, 2025 | -0.14 | -0.19 | +26.3% |
| May 5, 2025 | -0.15 | -0.24 | +37.5% |
| Feb 24, 2025 | -0.11 | -0.15 | +24.4% |
| Nov 12, 2024 | -0.16 | -0.22 | +27.3% |
| Aug 5, 2024 | -0.22 | -0.26 | +15.4% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
38No pass
Benjamin Graham
42No pass
Philip Fisher
48No pass
Peter Lynch
71Pass
Joel Greenblatt
2No pass
Charlie Munger
33No pass
Terry Smith
33No pass
Questions about SI-BONE
Is SI-BONE a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the SI-BONE AI analysis
What does SI-BONE do?
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It is in Medical - Devices.
Does SI-BONE pay a dividend?
No. SI-BONE does not pay a dividend at the moment.
Is SI-BONE stock halal?
Yes. SI-BONE passes our halal screen: its business is permitted and its debt is 3% of its market value, under the 30% limit. How we check
How has SI-BONE stock done over the past year?
Up 35.8% over the past twelve months, to $23.44. It traded between $11.61 and $25.60 and is 8.4% below its high.
Who are SI-BONE's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with SI-BONE's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.